Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

Kian Behbakht

Concepts (451)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Ovarian Neoplasms
44
2025
484
5.500
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
8
2024
90
1.300
 Why?
Peritoneal Neoplasms
7
2024
86
1.120
 Why?
Endometrial Neoplasms
10
2019
162
1.050
 Why?
Drug Resistance, Neoplasm
16
2024
752
0.990
 Why?
Antineoplastic Combined Chemotherapy Protocols
9
2020
1560
0.960
 Why?
Uterine Cervical Neoplasms
8
2017
230
0.930
 Why?
Genital Neoplasms, Female
6
2020
82
0.920
 Why?
Cystadenocarcinoma, Serous
6
2024
68
0.840
 Why?
Hysterectomy
4
2018
118
0.760
 Why?
Antineoplastic Agents
10
2023
2046
0.750
 Why?
Fallopian Tube Neoplasms
6
2024
15
0.720
 Why?
TNF-Related Apoptosis-Inducing Ligand
5
2017
44
0.660
 Why?
Biomarkers, Tumor
8
2019
1164
0.620
 Why?
Gelatin
2
2016
42
0.620
 Why?
Neoplasms, Glandular and Epithelial
3
2015
35
0.600
 Why?
Models, Economic
1
2018
53
0.580
 Why?
Thrombin
2
2016
145
0.580
 Why?
Claudin-4
4
2025
15
0.570
 Why?
Hyperthermia, Induced
1
2018
109
0.550
 Why?
Female
84
2025
68734
0.520
 Why?
Pelvic Infection
1
2016
4
0.520
 Why?
Cell Line, Tumor
20
2025
3186
0.520
 Why?
Homeodomain Proteins
3
2012
494
0.520
 Why?
Tissue Adhesives
1
2016
17
0.510
 Why?
Cost-Benefit Analysis
1
2018
569
0.490
 Why?
Neoplastic Cells, Circulating
2
2017
70
0.480
 Why?
Women
1
2015
52
0.460
 Why?
Neoplasm Recurrence, Local
6
2019
958
0.450
 Why?
Sirolimus
2
2016
270
0.430
 Why?
Vagina
6
2016
174
0.420
 Why?
Health Knowledge, Attitudes, Practice
2
2015
1280
0.390
 Why?
Antibodies, Neoplasm
1
2012
34
0.380
 Why?
Neoplasm Staging
15
2024
1282
0.380
 Why?
Humans
88
2025
129625
0.370
 Why?
Middle Aged
47
2024
31136
0.370
 Why?
Cisplatin
2
2015
299
0.370
 Why?
Histone-Lysine N-Methyltransferase
2
2024
124
0.350
 Why?
Aged
35
2024
22061
0.330
 Why?
Neoadjuvant Therapy
4
2020
379
0.330
 Why?
Pelvic Exenteration
1
2009
11
0.320
 Why?
Robotic Surgical Procedures
3
2016
115
0.320
 Why?
Apoptosis
8
2019
2492
0.320
 Why?
Leiomyosarcoma
3
2020
27
0.320
 Why?
Uterine Neoplasms
4
2019
101
0.320
 Why?
Paclitaxel
3
2019
217
0.310
 Why?
Phthalazines
2
2019
41
0.310
 Why?
Cytoreduction Surgical Procedures
2
2020
59
0.310
 Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
3
2017
29
0.310
 Why?
Aged, 80 and over
17
2020
7052
0.310
 Why?
Health Personnel
1
2015
653
0.310
 Why?
Pyrimidines
3
2019
459
0.310
 Why?
Tumor Microenvironment
2
2024
627
0.300
 Why?
Carcinoma, Endometrioid
3
2019
44
0.300
 Why?
Chemotherapy, Adjuvant
2
2020
377
0.290
 Why?
Caffeine
1
2008
62
0.290
 Why?
Carbazoles
1
2008
84
0.290
 Why?
Azepines
2
2019
88
0.290
 Why?
Clinical Competence
1
2015
1017
0.280
 Why?
Papanicolaou Test
2
2004
42
0.280
 Why?
Vaginal Smears
2
2004
55
0.270
 Why?
Postoperative Complications
6
2020
2477
0.270
 Why?
Piperazines
2
2019
340
0.270
 Why?
Protein Kinase C
1
2008
262
0.270
 Why?
Gene Expression Regulation, Neoplastic
7
2025
1336
0.250
 Why?
Adult
29
2020
35599
0.250
 Why?
Hemostasis, Surgical
2
2016
22
0.240
 Why?
Laparotomy
2
2015
106
0.230
 Why?
Adenocarcinoma
4
2015
893
0.230
 Why?
Urban Health
1
2004
79
0.230
 Why?
Genomic Instability
1
2025
48
0.230
 Why?
Disease-Free Survival
7
2017
646
0.230
 Why?
Fallopian Tubes
1
2024
30
0.220
 Why?
Prognosis
9
2024
3774
0.210
 Why?
Histocompatibility Antigens
2
2024
107
0.210
 Why?
Pyrazoles
2
2020
404
0.210
 Why?
Genetic Therapy
2
2014
289
0.210
 Why?
Uterine Cervical Dysplasia
2
2003
40
0.200
 Why?
Adenocarcinoma, Clear Cell
2
2021
13
0.200
 Why?
Neoplasm Grading
5
2024
282
0.190
 Why?
Leiomyoma
2
2019
73
0.190
 Why?
Healthcare Disparities
2
2018
578
0.180
 Why?
Hospitals, Public
1
2001
26
0.180
 Why?
BRCA2 Protein
3
2019
54
0.180
 Why?
Piperidines
2
2019
201
0.170
 Why?
Hospitals, University
1
2001
178
0.170
 Why?
Vulvar Neoplasms
1
2020
12
0.170
 Why?
Treatment Outcome
11
2020
10219
0.170
 Why?
Cervix Uteri
3
2011
49
0.170
 Why?
Mutation
5
2019
3717
0.170
 Why?
Epoxy Compounds
1
2020
33
0.170
 Why?
Carnitine O-Palmitoyltransferase
1
2020
45
0.160
 Why?
Rad51 Recombinase
1
2019
13
0.160
 Why?
Cell Movement
2
2016
948
0.160
 Why?
Enoxaparin
1
2020
59
0.160
 Why?
Neoplasms
4
2017
2455
0.160
 Why?
Up-Regulation
2
2020
840
0.160
 Why?
Vaccines, Conjugate
1
2019
63
0.160
 Why?
Receptors, Adiponectin
1
2019
19
0.160
 Why?
Poly(ADP-ribose) Polymerases
1
2019
94
0.160
 Why?
Interleukin-12
2
2014
118
0.150
 Why?
Sequence Analysis, RNA
2
2019
427
0.150
 Why?
Pyridones
1
2020
158
0.150
 Why?
CD8-Positive T-Lymphocytes
1
2024
855
0.150
 Why?
Patient Acceptance of Health Care
1
2004
761
0.150
 Why?
Lymph Node Excision
2
2020
164
0.150
 Why?
Adjuvants, Immunologic
1
2019
221
0.150
 Why?
Cancer Vaccines
1
2019
164
0.150
 Why?
Ovariectomy
2
2015
135
0.150
 Why?
Cost Savings
1
2018
78
0.150
 Why?
Sarcoma
1
2020
176
0.150
 Why?
Oncologists
1
2018
35
0.140
 Why?
Cell Growth Processes
2
2008
52
0.140
 Why?
Breast Neoplasms
4
2019
2133
0.140
 Why?
Pregnancy Complications, Infectious
1
2002
368
0.140
 Why?
Dose-Response Relationship, Drug
4
2008
2011
0.140
 Why?
Aurora Kinase A
1
2017
54
0.140
 Why?
Antineoplastic Agents, Phytogenic
1
2019
187
0.140
 Why?
Leukocyte Common Antigens
1
2017
82
0.140
 Why?
beta Catenin
1
2019
225
0.140
 Why?
Survival Rate
5
2020
1872
0.140
 Why?
Anion Transport Proteins
1
2017
9
0.140
 Why?
Fatty Acids
1
2020
427
0.130
 Why?
Salpingectomy
2
2015
13
0.130
 Why?
Sexual Dysfunctions, Psychological
1
2017
34
0.130
 Why?
Gestational Trophoblastic Disease
1
2016
5
0.130
 Why?
Curettage
1
2016
8
0.130
 Why?
Keratins
1
2017
175
0.130
 Why?
Animals
13
2024
35391
0.130
 Why?
Megestrol Acetate
1
2016
2
0.130
 Why?
Carcinoma, Neuroendocrine
1
2016
32
0.130
 Why?
Sexual Dysfunction, Physiological
1
2017
64
0.130
 Why?
Risk Factors
6
2016
9786
0.130
 Why?
Minority Groups
1
2018
249
0.130
 Why?
Venous Thromboembolism
1
2020
287
0.130
 Why?
Neoplasms, Squamous Cell
1
1996
4
0.130
 Why?
Colony Count, Microbial
1
2016
117
0.130
 Why?
Standard of Care
1
2016
71
0.130
 Why?
Medroxyprogesterone Acetate
1
2015
35
0.130
 Why?
Gynecology
1
2018
174
0.120
 Why?
Adenoviridae
1
1996
193
0.120
 Why?
Brachytherapy
1
2016
104
0.120
 Why?
Cell Survival
4
2025
1076
0.120
 Why?
Gene Expression Profiling
2
2019
1687
0.120
 Why?
Anticoagulants
1
2020
637
0.120
 Why?
Keratin-5
1
2015
50
0.120
 Why?
Molecular Targeted Therapy
1
2018
391
0.120
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2017
949
0.120
 Why?
Tamoxifen
1
2016
197
0.120
 Why?
Tretinoin
1
1996
130
0.120
 Why?
Chemoradiotherapy
1
2016
208
0.120
 Why?
Immunohistochemistry
3
2016
1685
0.120
 Why?
Combined Modality Therapy
4
2020
1203
0.120
 Why?
Mice
9
2024
16961
0.120
 Why?
Antineoplastic Agents, Hormonal
1
2015
155
0.120
 Why?
CA-125 Antigen
2
2008
14
0.110
 Why?
Abdominal Abscess
1
2014
26
0.110
 Why?
Surgeons
1
2018
264
0.110
 Why?
Mice, SCID
2
2012
350
0.110
 Why?
Reoperation
1
2016
541
0.110
 Why?
Kaplan-Meier Estimate
4
2020
851
0.110
 Why?
Immunotherapy
1
2018
596
0.110
 Why?
Lipid Metabolism
1
2017
503
0.110
 Why?
Endometrium
1
2014
56
0.110
 Why?
Glycoproteins
1
2015
338
0.110
 Why?
Cell Cycle
2
2025
588
0.110
 Why?
Cytokines
1
2002
2021
0.110
 Why?
Quality of Health Care
1
2018
604
0.110
 Why?
Interpersonal Relations
1
2017
394
0.110
 Why?
Transforming Growth Factor beta
1
1996
460
0.100
 Why?
Proto-Oncogene Proteins c-akt
2
2016
432
0.100
 Why?
Pelvic Neoplasms
1
2013
19
0.100
 Why?
Models, Biological
3
2019
1724
0.100
 Why?
Young Adult
5
2020
12455
0.100
 Why?
Antigens, CD
1
2015
487
0.100
 Why?
Plasmids
1
2014
359
0.100
 Why?
Genes, Tumor Suppressor
3
1998
87
0.100
 Why?
RNA, Messenger
2
2012
2708
0.100
 Why?
Escherichia coli
1
2016
767
0.100
 Why?
Gardnerella vaginalis
2
2002
4
0.100
 Why?
Antibody Specificity
1
2012
184
0.090
 Why?
Neoplastic Stem Cells
1
2015
378
0.090
 Why?
Cell Division
2
2008
796
0.090
 Why?
Endocrine Gland Neoplasms
1
2011
1
0.090
 Why?
Transplantation, Heterologous
1
2012
192
0.090
 Why?
RNA, Small Interfering
3
2020
591
0.090
 Why?
Cyclin D1
1
2011
63
0.090
 Why?
Drug Synergism
2
2011
370
0.090
 Why?
Proteasome Inhibitors
1
2011
42
0.090
 Why?
MicroRNAs
1
2017
679
0.090
 Why?
Adenocarcinoma, Mucinous
1
2011
73
0.090
 Why?
DNA
1
2017
1404
0.090
 Why?
Peptides
1
2015
926
0.080
 Why?
Transfection
2
2007
915
0.080
 Why?
Cell Proliferation
4
2019
2373
0.080
 Why?
Cadherins
1
2011
190
0.080
 Why?
Neoplasm Invasiveness
3
2016
481
0.080
 Why?
Lymphoma
1
2011
199
0.080
 Why?
Inflammation
1
2020
2750
0.080
 Why?
Age Factors
5
2016
3152
0.080
 Why?
Skin Transplantation
1
2009
84
0.080
 Why?
Anastomosis, Surgical
1
2009
149
0.080
 Why?
Adolescent
5
2020
20412
0.080
 Why?
Adaptor Proteins, Signal Transducing
1
2011
399
0.080
 Why?
Papillomaviridae
2
2002
114
0.080
 Why?
Urokinase-Type Plasminogen Activator
1
2008
29
0.080
 Why?
G2 Phase
1
2008
36
0.070
 Why?
TOR Serine-Threonine Kinases
1
2011
398
0.070
 Why?
Radiation-Protective Agents
1
2008
26
0.070
 Why?
Rectum
1
2009
170
0.070
 Why?
Case-Control Studies
4
2019
3378
0.070
 Why?
Models, Statistical
1
2011
625
0.070
 Why?
Heterografts
2
2019
133
0.070
 Why?
Genes, BRCA1
2
1998
32
0.070
 Why?
Class I Phosphatidylinositol 3-Kinases
2
2019
81
0.070
 Why?
Microsatellite Instability
2
2019
37
0.070
 Why?
Urinary Bladder
1
2009
175
0.070
 Why?
Cell Culture Techniques
2
2020
338
0.070
 Why?
Xenograft Model Antitumor Assays
2
2020
808
0.070
 Why?
Cysteine
1
2008
195
0.070
 Why?
Tumor Suppressor Protein p53
3
2019
507
0.070
 Why?
Gynecologic Surgical Procedures
2
2020
57
0.060
 Why?
PTEN Phosphohydrolase
2
2019
161
0.060
 Why?
Double-Blind Method
3
2019
1875
0.060
 Why?
Proportional Hazards Models
3
2020
1198
0.060
 Why?
Retrospective Studies
6
2020
14522
0.060
 Why?
Adenosarcoma
2
2005
2
0.060
 Why?
Models, Animal
1
2008
378
0.060
 Why?
Follow-Up Studies
4
2020
4894
0.060
 Why?
Length of Stay
3
2015
1122
0.060
 Why?
Signal Transduction
4
2012
4931
0.060
 Why?
Polymerase Chain Reaction
4
2002
1035
0.060
 Why?
Indazoles
2
2019
66
0.060
 Why?
Colposcopy
2
2003
15
0.060
 Why?
Ovary
1
2007
209
0.060
 Why?
Intestinal Neoplasms
1
2005
28
0.060
 Why?
Cell Count
2
2015
312
0.060
 Why?
Neoplasm Proteins
3
1998
419
0.060
 Why?
United States
5
2022
13871
0.060
 Why?
Germ-Line Mutation
2
1996
142
0.060
 Why?
Ultraviolet Rays
1
2008
382
0.060
 Why?
Sexual Behavior
1
2009
481
0.060
 Why?
Chicago
1
2004
57
0.060
 Why?
Disease Progression
3
2019
2627
0.060
 Why?
Tumor Cells, Cultured
2
1996
943
0.060
 Why?
Peptide Fragments
1
2008
693
0.060
 Why?
Antioxidants
1
2008
558
0.060
 Why?
Transcription Factors
4
2011
1647
0.060
 Why?
Blood Loss, Surgical
2
2015
93
0.060
 Why?
Survival Analysis
4
2020
1269
0.050
 Why?
Activating Transcription Factor 6
1
2023
17
0.050
 Why?
Receptors, Estrogen
2
2015
422
0.050
 Why?
Transcription Factor AP-1
1
2023
88
0.050
 Why?
X-ray Repair Cross Complementing Protein 1
1
2022
13
0.050
 Why?
Neoplasm Metastasis
2
2015
611
0.050
 Why?
Medical Oncology
1
2024
269
0.050
 Why?
Vaginal Neoplasms
1
2001
12
0.050
 Why?
Risk Assessment
3
2016
3262
0.050
 Why?
Trichomonas vaginalis
1
2002
13
0.050
 Why?
Gene Expression
1
2007
1465
0.050
 Why?
Phosphatidylinositol 3-Kinases
2
2016
361
0.050
 Why?
Yeasts
1
2002
52
0.050
 Why?
Women's Health
1
2004
364
0.050
 Why?
Vaginosis, Bacterial
1
2001
12
0.050
 Why?
Cell Nucleus
1
2025
584
0.050
 Why?
Vaginal Diseases
1
2001
21
0.050
 Why?
Pregnancy
3
2016
6417
0.040
 Why?
Endometriosis
1
2001
46
0.040
 Why?
DNA, Neoplasm
2
1998
157
0.040
 Why?
DNA Primers
1
2002
511
0.040
 Why?
Vulvectomy
1
2020
2
0.040
 Why?
Epithelial Cells
1
2007
1075
0.040
 Why?
Histiocytoma, Malignant Fibrous
1
2020
5
0.040
 Why?
Databases, Factual
2
2016
1269
0.040
 Why?
Dermatofibrosarcoma
1
2020
9
0.040
 Why?
Hospitals, Urban
1
2001
133
0.040
 Why?
DNA Repair
1
2022
210
0.040
 Why?
Clinical Trials, Phase I as Topic
1
2020
51
0.040
 Why?
Alleles
3
2017
847
0.040
 Why?
Medically Uninsured
1
2001
127
0.040
 Why?
Liposarcoma
1
2020
27
0.040
 Why?
Anoikis
1
2020
31
0.040
 Why?
Prospective Studies
4
2016
7135
0.040
 Why?
Hemocyanins
1
2019
62
0.040
 Why?
Interleukin-10
1
2002
300
0.040
 Why?
Diagnosis, Differential
2
2019
1432
0.040
 Why?
Rhabdomyosarcoma
1
2020
64
0.040
 Why?
Chitinase-3-Like Protein 1
1
2019
19
0.040
 Why?
DNA Damage
1
2022
384
0.040
 Why?
Logistic Models
1
2004
1986
0.040
 Why?
Radiotherapy
1
2020
185
0.040
 Why?
SEER Program
1
2020
202
0.040
 Why?
Neoplasms, Cystic, Mucinous, and Serous
1
2019
25
0.040
 Why?
Enzyme-Linked Immunosorbent Assay
1
2002
834
0.040
 Why?
Lymphatic Metastasis
1
2020
320
0.040
 Why?
Intramolecular Oxidoreductases
1
2019
67
0.040
 Why?
Poly-ADP-Ribose Binding Proteins
1
2019
33
0.040
 Why?
DNA Polymerase II
1
2019
38
0.040
 Why?
Gene Knockdown Techniques
1
2020
317
0.040
 Why?
Chromosomes, Human, Pair 7
1
1998
15
0.040
 Why?
Cell Cycle Checkpoints
1
2019
95
0.040
 Why?
Cytoskeletal Proteins
1
2019
148
0.040
 Why?
Mechanistic Target of Rapamycin Complex 1
1
2019
119
0.040
 Why?
Mitosis
1
2019
180
0.040
 Why?
Microtubule-Associated Proteins
1
2019
192
0.040
 Why?
Europe
1
2019
363
0.040
 Why?
AMP-Activated Protein Kinases
1
2019
191
0.040
 Why?
Interleukin-6
1
2002
723
0.040
 Why?
Interleukin-1
1
2002
961
0.040
 Why?
Colorectal Neoplasms, Hereditary Nonpolyposis
1
1998
33
0.040
 Why?
Image Cytometry
1
2017
7
0.040
 Why?
Wnt Signaling Pathway
1
2019
170
0.030
 Why?
Chromosomes, Human, Pair 14
1
1997
19
0.030
 Why?
Ganciclovir
1
1996
52
0.030
 Why?
Chromosome Deletion
1
1997
104
0.030
 Why?
Socioeconomic Factors
1
2001
1213
0.030
 Why?
Hospitals, Private
1
2016
12
0.030
 Why?
Health Facility Size
1
2016
11
0.030
 Why?
Time Factors
2
2019
6555
0.030
 Why?
Chorionic Gonadotropin
1
2016
79
0.030
 Why?
Indoles
1
2019
383
0.030
 Why?
Oxidation-Reduction
1
2020
1028
0.030
 Why?
Mass Spectrometry
1
2019
714
0.030
 Why?
Cell Differentiation
2
2011
1891
0.030
 Why?
Ifosfamide
1
1996
34
0.030
 Why?
AC133 Antigen
1
2015
19
0.030
 Why?
Cell Separation
1
2017
317
0.030
 Why?
Cell Line, Transformed
1
1996
141
0.030
 Why?
RNA-Binding Proteins
1
2019
387
0.030
 Why?
Marriage
1
2017
114
0.030
 Why?
Tissue Array Analysis
1
2015
55
0.030
 Why?
Hospital Charges
1
1996
42
0.030
 Why?
Hospitals, Teaching
1
2016
114
0.030
 Why?
Caspase 3
1
2016
245
0.030
 Why?
Cystadenocarcinoma, Papillary
1
1995
5
0.030
 Why?
Carboplatin
1
1996
139
0.030
 Why?
Tumor Burden
1
2016
286
0.030
 Why?
Cell Cycle Proteins
1
2019
584
0.030
 Why?
Disease Management
1
2019
588
0.030
 Why?
Ataxia Telangiectasia Mutated Proteins
1
2015
66
0.030
 Why?
DNA Mismatch Repair
1
2015
47
0.030
 Why?
Ileus
1
2015
12
0.030
 Why?
Genes, p53
1
1995
70
0.030
 Why?
Income
1
2016
188
0.030
 Why?
Urinary Retention
1
2015
20
0.030
 Why?
Elective Surgical Procedures
1
2016
164
0.030
 Why?
Female Urogenital Diseases
1
2014
5
0.030
 Why?
RNA Interference
1
2016
450
0.030
 Why?
Taxoids
1
2015
98
0.030
 Why?
Antigens, Neoplasm
1
2017
308
0.030
 Why?
Intraoperative Complications
1
2015
129
0.030
 Why?
Morbidity
1
2015
302
0.030
 Why?
Receptors, Androgen
1
2015
143
0.030
 Why?
Sensitivity and Specificity
1
2019
1843
0.030
 Why?
Multivariate Analysis
2
1996
1499
0.030
 Why?
Drug Administration Schedule
1
2016
767
0.030
 Why?
Histones
1
2019
589
0.030
 Why?
Blood Volume
1
2014
60
0.030
 Why?
Reference Values
1
1996
794
0.030
 Why?
Bevacizumab
1
2015
128
0.030
 Why?
Bleomycin
1
1996
243
0.030
 Why?
Point Mutation
1
1995
224
0.030
 Why?
Infusions, Parenteral
1
2014
38
0.030
 Why?
Polyethyleneimine
1
2014
18
0.030
 Why?
Pelvis
1
2015
104
0.030
 Why?
Hemostatics
1
2014
50
0.030
 Why?
DNA, Viral
1
1996
347
0.030
 Why?
Deoxycytidine
1
2015
164
0.030
 Why?
Insurance, Health
1
2016
267
0.030
 Why?
Tumor Suppressor Proteins
1
2016
314
0.030
 Why?
Receptors, Progesterone
1
2015
341
0.030
 Why?
Drainage
1
2014
164
0.030
 Why?
Anemia
1
2015
161
0.030
 Why?
Lipids
1
2017
627
0.030
 Why?
Preoperative Care
1
2015
338
0.030
 Why?
Urban Population
1
2016
443
0.030
 Why?
Thrombocytopenia
1
2015
186
0.030
 Why?
Gene Transfer Techniques
1
2014
161
0.030
 Why?
Patient Readmission
1
2018
653
0.030
 Why?
Referral and Consultation
1
2018
730
0.030
 Why?
Polymorphism, Single-Stranded Conformational
3
1998
28
0.030
 Why?
Ultrasonography
1
2016
712
0.020
 Why?
Membrane Proteins
1
2019
1125
0.020
 Why?
Biomarkers
1
2024
3968
0.020
 Why?
Linear Models
1
1994
819
0.020
 Why?
Rural Population
1
2016
516
0.020
 Why?
Cholesterol
1
2014
412
0.020
 Why?
Zinc Finger E-box-Binding Homeobox 1
1
2011
23
0.020
 Why?
Perioperative Period
1
2011
49
0.020
 Why?
Analysis of Variance
1
1994
1293
0.020
 Why?
Protein Kinase Inhibitors
1
2017
887
0.020
 Why?
Mutant Proteins
1
2011
100
0.020
 Why?
Comorbidity
1
2016
1547
0.020
 Why?
DNA Fragmentation
1
2011
44
0.020
 Why?
Risk Reduction Behavior
1
2013
209
0.020
 Why?
Fas Ligand Protein
1
2011
58
0.020
 Why?
Tomography, X-Ray Computed
2
2014
2512
0.020
 Why?
Hyperplasia
1
2011
175
0.020
 Why?
Neovascularization, Pathologic
1
2012
296
0.020
 Why?
Neoplasm Transplantation
1
2011
256
0.020
 Why?
Administration, Oral
1
2012
787
0.020
 Why?
Polymorphism, Single Nucleotide
1
2017
2060
0.020
 Why?
Antibodies, Monoclonal, Humanized
1
2015
757
0.020
 Why?
Epithelial-Mesenchymal Transition
1
2011
201
0.020
 Why?
Pregnancy Complications
1
2014
493
0.020
 Why?
Anti-Bacterial Agents
2
2014
1705
0.020
 Why?
Polyethylene Glycols
1
2014
589
0.020
 Why?
Regression Analysis
1
2011
997
0.020
 Why?
Receptors, Urokinase Plasminogen Activator
1
2008
15
0.020
 Why?
Patient Discharge
1
2015
836
0.020
 Why?
Quality of Life
1
2020
2688
0.020
 Why?
Injections, Subcutaneous
1
2008
147
0.020
 Why?
Blotting, Western
1
2011
1206
0.020
 Why?
Placebos
1
2008
201
0.020
 Why?
Mice, Hairless
1
2008
60
0.020
 Why?
Enzyme Inhibitors
1
2011
827
0.020
 Why?
Sulfonamides
1
2011
497
0.020
 Why?
Quality Improvement
1
2015
1101
0.020
 Why?
Molecular Sequence Data
3
1996
2835
0.020
 Why?
Chromosome Mapping
2
1998
505
0.020
 Why?
Genetic Markers
2
1998
336
0.020
 Why?
Receptors, Cell Surface
1
2008
381
0.020
 Why?
Disease Models, Animal
1
2016
4078
0.020
 Why?
Frameshift Mutation
2
1996
32
0.020
 Why?
Cross-Sectional Studies
1
2017
5075
0.020
 Why?
Gene Deletion
2
1998
382
0.020
 Why?
Carcinosarcoma
1
2005
16
0.020
 Why?
Cohort Studies
1
2015
5426
0.010
 Why?
DNA Mutational Analysis
2
1996
382
0.010
 Why?
Colorado
1
2014
4404
0.010
 Why?
Severity of Illness Index
1
2011
2739
0.010
 Why?
Obesity
1
2016
2882
0.010
 Why?
Base Sequence
2
1996
2147
0.010
 Why?
Electrophoresis, Gel, Pulsed-Field
1
2001
21
0.010
 Why?
Metronidazole
1
2001
20
0.010
 Why?
Genes, rRNA
1
2001
41
0.010
 Why?
Microbial Sensitivity Tests
1
2001
348
0.010
 Why?
DNA, Bacterial
1
2001
321
0.010
 Why?
RNA, Ribosomal, 16S
1
2001
524
0.010
 Why?
Loss of Heterozygosity
1
1998
46
0.010
 Why?
Microsatellite Repeats
1
1998
164
0.010
 Why?
Actuarial Analysis
1
1996
26
0.010
 Why?
Ecosystem
1
2001
560
0.010
 Why?
Genes, Neoplasm
1
1995
20
0.010
 Why?
BRCA1 Protein
1
1995
66
0.010
 Why?
Sequence Analysis, DNA
1
1998
778
0.010
 Why?
Age of Onset
1
1996
495
0.010
 Why?
Introns
1
1995
251
0.010
 Why?
Exons
1
1995
342
0.010
 Why?
Amino Acid Sequence
1
1995
2057
0.010
 Why?
Male
1
2017
63670
0.010
 Why?
Behbakht's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (451) concept(s)
_
Co-Authors Expand Description
See all (56) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)